Elisa Chia Elisa has been in journalism for more than 20 years and is now a correspondent at The Straits Times.

French pharma group Servier has formed a second partnership with Aitia focusing on the use of artificial intelligence and digital twins to help discover and develop new therapies for cancer. The ...

FDA and EMA start speedy reviews of Servier’s vorasidenib for IDH-mutated low-grade glioma, hoping to end decades of stagnation in therapies for the brain cancer.

Mutant IDH Glioma - Clinical Expert ExchangeMutant IDH Glioma - Clinical Expert Exchange Welcome to the Global mIDH1/2 Glioma Hub. Vorasidenib is the first effective targeted therapy for the ...